Search details
1.
Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective.
Semin Cancer Biol
; 86(Pt 3): 997-1007, 2022 11.
Article
in English
| MEDLINE | ID: mdl-34838957
2.
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
Br J Cancer
; 128(7): 1391-1399, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36759721
3.
Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study.
Mol Med
; 29(1): 14, 2023 01 30.
Article
in English
| MEDLINE | ID: mdl-36717774
4.
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.
Int J Mol Sci
; 23(2)2022 Jan 13.
Article
in English
| MEDLINE | ID: mdl-35055006
5.
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Br J Cancer
; 124(1): 183-190, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33024268
6.
Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
Future Oncol
; 17(18): 2315-2324, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-33663264
7.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 21(4): 497-507, 2020 04.
Article
in English
| MEDLINE | ID: mdl-32164906
8.
Intestinal adenosquamous carcinoma with a synchronous skin metastasis: a immunohistochemical and molecular analysis.
Int J Colorectal Dis
; 35(2): 337-341, 2020 Feb.
Article
in English
| MEDLINE | ID: mdl-31823050
9.
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.
Pharmacogenomics J
; 19(6): 556-563, 2019 12.
Article
in English
| MEDLINE | ID: mdl-30723313
10.
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial.
Front Oncol
; 13: 1069370, 2023.
Article
in English
| MEDLINE | ID: mdl-36860319
11.
Mucosal Microbiota from Colorectal Cancer, Adenoma and Normal Epithelium Reveals the Imprint of Fusobacterium nucleatum in Cancerogenesis.
Microorganisms
; 11(5)2023 Apr 28.
Article
in English
| MEDLINE | ID: mdl-37317121
12.
Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model.
Cell Death Discov
; 9(1): 116, 2023 Apr 05.
Article
in English
| MEDLINE | ID: mdl-37019893
13.
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer.
Crit Rev Oncol Hematol
; 173: 103657, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35337969
14.
Butyrate, a postbiotic of intestinal bacteria, affects pancreatic cancer and gemcitabine response in in vitro and in vivo models.
Biomed Pharmacother
; 151: 113163, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35617803
15.
Immunotherapy in advanced anal cancer: Is the beginning of a new era?
Cancer Treat Rev
; 105: 102373, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35279535
16.
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941.
Cancers (Basel)
; 14(16)2022 Aug 12.
Article
in English
| MEDLINE | ID: mdl-36011056
17.
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
Cancer Treat Rev
; 103: 102326, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-35016085
18.
High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome.
Int J Cancer
; 129(3): 536-45, 2011 Aug 01.
Article
in English
| MEDLINE | ID: mdl-21064098
19.
Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels.
Biomolecules
; 11(5)2021 04 26.
Article
in English
| MEDLINE | ID: mdl-33925948
20.
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study).
Curr Oncol
; 28(3): 1761-1772, 2021 05 08.
Article
in English
| MEDLINE | ID: mdl-34066784